Biology Reference
In-Depth Information
64. Rigotti A (2007) Absorption, transport, and tissue delivery of vitamin E. Mol Aspects Med
28(5-6):423-436
65. Kubo T, Takei Y, Mihara K, Yanagihara K, Seyama T (2012) Amino-modi fi ed and lipid-
conjugated dicer-substrate siRNA enhances RNAi efficacy. Bioconjug Chem 23(2):164-173
66. Kariko K, Buckstein M, Ni H, Weissman D (2005) Suppression of RNA recognition by Toll-
like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.
Immunity 23(2):165-175
67. Robbins M, Judge A, Liang L, McClintock K, Yaworski E, Maclachlan I (2007) 2'-O-methyl-
modified RNAs Act as TLR7 Antagonists. Mol Ther 15(9):1663-1669
68. Gantier MP, Williams BR (2007) The response of mammalian cells to double-stranded RNA.
Cytokine Growth Factor Rev 18(5-6):363-371
69. Robbins M, Judge A, MacLachlan I (2009) siRNA and innate immunity. Oligonucleotides
19(2):89-102
70. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D et al (2006)
Induction of the interferon response by siRNA is cell type- and duplex length-dependent.
RNA 12(6):988-993
71. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, Marshall W et al (2005) Different
delivery methods-different expression profiles. Nat Methods 2(4):241
72. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R et al
(2006) A structural basis for discriminating between self and nonself double-stranded RNAs
in mammalian cells. Nat Biotechnol 24(5):559-565
73. Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13(4):644-670
74. Rettig GR, Behlke MA (2012) Progress towards in vivo use of siRNAs-II. Mol Ther
20:483-512
75. Lundberg P, Welander PV, Edwards CK 3rd, van Rooijen N, Cantin E (2007) Tumor necrosis
factor (TNF) protects resistant C57BL/6 mice against herpes simplex virus-induced encepha-
litis independently of signaling via TNF receptor 1 or 2. J Virol 81(3):1451-1460
76. Lundberg P, Yang H-J, Jung S-J, Behlke MA, Rose SD, Cantin EM (2012) Protection against
TNFa-dependent liver toxicity by intraperitoneal liposome delivered DsiRNA targeting
TNFa in vivo. J Control Release 160:194-199
77. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J (2008) Chitosan/
siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-
inflammatory treatment in a murine arthritis model. Mol Ther 17(1):162-168
78. Nawroth I, Alsner J, Behlke MA, Besenbacher F, Overgaard J, Howard KA et al (2010)
Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFalpha pre-
vents radiation-induced fibrosis. Radiother Oncol 97(1):143-148
79. Dore-Savard L, Roussy G, Dansereau MA, Collingwood MA, Lennox KA, Rose SD et al
(2008) Central delivery of Dicer-substrate siRNA: a direct application for pain research. Mol
Ther 16(7):1331-1339
80. LaCroix-Fralish ML, Mo G, Smith SB, Sotocinal SG, Ritchie J, Austin JS et al (2009) The
beta3 subunit of the Na+, K + -ATPase mediates variable nociceptive sensitivity in the forma-
lin test. Pain 144(3):294-302
81. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y et al (2008) Resolution of liver cir-
rhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chap-
erone. Nat Biotechnol 26(4):431-442
82. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M et al (2009)
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances anti-
tumor immune responses. Nat Biotechnol 27(10):925-932
83. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H et al (2011) An aptamer-siRNA chi-
mera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in human-
ized mice. Sci Transl Med 3(66):66ra6
84. Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD et al (2011) Systemic administration of
combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in human-
ized mice. Mol Ther 19(12):2228-2238
Search WWH ::




Custom Search